Abstract
Posttraumatic stress disorder is triggered by an external event that threatening individual physical integrity, leading to characteristics symptoms of reviviscence, avoidance/numbing and hyperarousal. Despite the external adverse event, some predisposing factors are present presupposing multicausality. Once PTSD is installed, it has chronic features leading to important functional impairment. Many biological dysfunctions have been described associated with PTSD, including an altered stress response system suggesting a corresponding increase allostatic load. We hypothesized that this increased allostatic load will lead to neurodegeneration that we will call neuroprogression. We propose to evaluate if there are a correspondence between clinical and neurobiological functioning associated to disease progression. We will evaluate and follow-up 120 outpatients with PTSD triggered by sexual abuse. We choose the event as it is often at our city, and as it is a high risk factor for PTSD development. We will have also a control group with 120 subjects without history of trauma or abuse and without psychiatric diagnostic paired by gender and age. Subjects will be evaluate at inclusion related to sociodemographic data, diagnostic, history of child maltreatment, for symptoms severity, functioning and quality of life, also they will classified by time-interval between trauma and symptoms onset until their firs evaluation for the present study. All patients will receive standard treatment for PTSD according to violence program guideline. Many evaluations will be executed including biological markers as: genetics, biochemical, molecular and image. Neuropsychological data and sleep evaluation will be performed, at inclusion and at each six months during one-year period. Patients will be enrolled on a head-to-head randomized controlled clinical trial to compare efficacy of two treatments known as effective in PTSD: fluoxetine Interpersonal therapy (IPT) during 12-weeks. Non responders will enrolled on a cross-over second phase, when those on IPT will receive fluoxetine, and those receiving medication will receive IPT. Crossing response and remission data with biomarker could be useful as predictive biomarkers of therapeutic response. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |